Jason S. Carter - 21 Nov 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: Chief Legal Officer
Issuer ticker: VERA
Reported as of: 21 Nov 2025
Net transaction value: -$107,498
SEC form: 4
Accepted by SEC: 25 Nov 2025, 16:05:05 UTC
Prior SEC filing: 20 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Jason S. Carter filed Form 4 for Vera Therapeutics, Inc. (VERA) on 25 Nov 2025.

Key facts

This page summarizes Jason S. Carter's Form 4 filing for Vera Therapeutics, Inc. (VERA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Nov 2025, 16:05.

Change

Previous filing in this sequence was filed on 20 Nov 2024.
Current net transaction value: -$107,498.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002045094 Primary reporting owner

Carter Jason S

Relationship: Chief Legal Officer
Address: C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERA transaction

Class A Common Stock

Sale

Transaction value: $107,498
Shares: -3,864
Change %: -7.3%
Price: $27.82
Shares after: 49,136
Date: 21 Nov 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Footnote F2

The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.19 to $28.035, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.